Please note: The University of Texas Health Science Center at San Antonio will now be called "UT Health San Antonio."

Search Program Faculty/Research

Gangadhara Sareddy, Ph.D.

Picture sareddy


Dr. Gangadhara Reddy Sareddy is currently employed at The University of Texas Health at San Antonio, in the Department of Obstetrics and Gynecology. He attended Sri Krishnadevaraya University (India) and received his Bachelors in Biology, followed by Masters in Biochemistry. He received his Ph.D. in Animal Sciences from the University of Hyderabad (India). Dr. Sareddy studies are focused on hormonal signaling and epigenetic mechanisms in glioblastoma and gynecologic malignancies. Dr. Sareddy’s current research interest include: 1) understanding the significance of histone lysine demethylase KDM1A and nuclear receptor signaling in glioma stem cells and hypoxia 2) studying the tumor suppressor functions of estrogen receptor beta signaling in ovarian cancer progression and therapy resistance.


Raj GV, Sareddy GR, Ma S, Lee T, Viswanadhapalli S, Li R, Liu X, Murakami S,Chen C, Lee W, Mann M, Krishnan SR, Manandhar B, Gonugunta VK, Strand D, Tekmal RR, Ahn J, Vadlamudi RK. Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers eLife 2017 Aug;.

Liu J, Viswanadhapalli S, Garcia L, Zhou M, Nair BC, Kost E, Tekmal RR, Li R, Rao MK, Curiel T, Vadlamudi RK, Sareddy GR. Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer Oncotarget (in press) 2017 Apr;.

Sareddy GR, Viswanadhapalli S, Surapaneni P, Suzuki T, Brenner A, Vadlamudi RK. Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway Oncogene 2017 Apr;36(17):2423-2434.

Sareddy G, Li X, Liu J, Garcia L, Viswanadhapalli S, Gruslova A, Garcian M, Strom A, Gustaffson J-A, Tekmal RR, Brenner A, Vadlamudi RK. Selective Estrogen Receptor β agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma Sci Rep 2016 Apr;.

Clark CA, Gupta HB, Sareddy GR, Pandeswara S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K, Liu Y, Turk MJ, Thedieck K, Hurez V, Li R, Vadlamudi R, Curiel TJGR. Tumor intrinsic PD-L1 signals regulate cell growth, pathogenesis and autophagy in ovarian cancer and melanoma Cancer Res 2016 Jan;76:6964-6974.

Gupta HB, Clark CA, Yuan B, Sareddy GR, Pandeswara S, Padron AS, Hurez V, Garcia J, Vadlamudi RK, Li R, Curiel TJ. Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer Signal Transduction and Targeted Therapy 2016 Jan;1.

Thakkar R, Wang R, Sareddy G, Wang J, Thiruvaiyaru D, Vadlamudi R, Zhang Q, Brann D. NLRP3 Inflammasome Activation in the Brain after Global Cerebral Ischemia and Regulation by 17β-Estradiol Oxid Med Cell Longev 2016 Jan;.

Sareddy GR, Zhang Q, Wang R, Scott E, Zou Y, O?Connor JC, Chen Y, Dong Y, Vadlamudi RK, Brann D. Proline-, glutamic acid-, and leucine-rich protein 1 mediates estrogen rapid signaling and neuroprotection in the brain Proc Natl Acad Sci U S A 2015 Dec;112:E6673--82.

Krishnan SR, Nair BC, Sareddy GR, Roy SS, Natarajan M, Suzuki T, Peng Y, Raj G, Vadlamudi RK. Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells Breast Cancer Res Treat 2015 Jan;150(3):487-499.

Nair BC, Krishnan SR, Sareddy GR, Mann M, Xu B, Natarajan M, Hasty P, Brann D, Tekmal RR, Vadlamudi RK. Proline, glutamic acid and leucine-rich protein-1 is essential for optimal p53-mediated DNA damage response Cell Death Differ 2014 Sep;21(9):1409-1418.

Gonugunta V, Sareddy GR, Krishnan SR, Cortez V, Saha Roy S, Tekmal RR, Vadlamudi RK. Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance Mol Cancer Ther 2014 Jan;13(1578):1578-1588.

Zhang Q, Wang R, Tang H, Dong Y, Chan A, Sareddy GR, Vadlamudi RK, and Brann DW. Brain-Derived Estrogen Exerts Anti-inflammatory and Neuroprotective Actions in the Rat Hippocampus Mol Cell Endocrinol 2014 Jan;389:84-91.

Sareddy GR, Kesanakurti D, Kirti PB, Babu PP. Nonsteroidal anti-inflammatory drugs diclofenac and celecoxib attenuates Wnt/β-catenin/Tcf signaling pathway in human glioblastoma cells Neurochem Res 2013 Jan;38:2313-2322.

Sareddy GR, Nair BC, Krishnan SK, Gonugunta VK, Zhang QG, Suzuki T, Miyata N, Brenner AJ, Brann DW, Vadlamudi RK. KDM1 is a novel therapeutic target for the treatment of gliomas Oncotarget 2013 Jan;4(1):18-28.

Zhang QG, Wang RM, Scott E, Han D, Dong Y, Tu JY, Yang F, Reddy Sareddy G, Vadlamudi RK, Brann DW. Hypersensitivity of the hippocampal CA3 region to stress-induced neurodegeneration and amyloidogenesis in a rat model of surgical menopause Brain 2013 Jan;136:1432-1445.

Sareddy GR, Nair BC, Gonugunta VK, Zhang QG, Brenner A, Brann DW, Tekmal RR, Vadlamudi RK. Therapeutic significance of estrogen receptor β agonists in gliomas Mol Cancer Ther 2012 Jan;11:1174-1182.

Assistant Professor



Ph.D., Animal Sciences (Cancer Biology), University of Hyderabad, 2010

M.S., Biochemistry, Sri Krishnadevaraya University, 2005


Phone: 210-567-4912